World Drug and Medication: Alcohol Addiction – Pipeline Review, H1 2012

• Publication date: April 2013
• Report size: 88 pages

This report provides data on the therapeutic development for Alcohol Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alcohol Addiction. 'Alcohol Addiction - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings...

This report provides data on the therapeutic development for Alcohol Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alcohol Addiction. 'Alcohol Addiction - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Alcohol Addiction.
- A review of the Alcohol Addiction products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alcohol Addiction pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Alcohol Addiction therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Drug And Medication Industry

Table of Contents
Data table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global March kets Direct Report Coverage 10
Alcohol Addiction Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Alcohol Addiction 12
Alcohol Addiction Therapeutics under Development by Firms 14
Alcohol Addiction Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Alcohol Addiction Therapeutics – Products under Development by Firms 23
Alcohol Addiction Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Alcohol Addiction Therapeutics Development 26
Eli Lilly and Firms 26
Tekmira Pharmaceuticals Corp. 27
Alkermes, Inc. 28
Mitsubishi Tanabe Pharma Corporation 29
Nippon Shinyaku Co., Ltd. 30
Catalyst Pharmaceutical Partners, Inc. 31
Biotie Therapies Corp. 32
Sihuan Pharmaceutical Holdings Group Ltd. 33
Alcohol Addiction – Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
Selincro - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
LY2456302 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ALKS 33 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CPP-109 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NS-11 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Modafinil - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Tenex - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Chantix - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Depakote ER - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Zofran - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
April epitant - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Neurontin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Zyban - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Naltrexone + Aripiprazole - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Acamprosate + Yohimbine + Mcpp - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Nicoderm CQ + Nicotine Nasal Spray - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Gabapentin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Levetiracetam XR - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Oxytocin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Atomoxetine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Prozac - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GSK561679 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Naltrexone + Modafinil - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Olanzapine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Duloxetine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Quetiapine + Mirtazapine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
LY2196044 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Pregabalin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Ondansetron + Topiramate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Citalopram - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Varenicline - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Seroquel - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
N-Acetylcysteine + Naltrexone - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Propranolol - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Pexacerfont - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Seroquel - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Prazosin - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Champix - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
AD01 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
AD04 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Topiramate + Naltrexone - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Ondansetron + Topiramate + Naltrexone - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Sulfasalazine - Drug Profile 90
Product Description 95
Mechanism of Action 95
R&D Progress 95
MT-7716 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Metadoxine - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Drug For Alcohol Addiction And Anxiety Disorders - Drug Profile 99
Product Description 101
Mechanism of Action 101
R&D Progress 101
Alcohol Addiction Therapeutics – Drug Profile Updates 102
Alcohol Addiction Therapeutics – Discontinued Products 105
Alcohol Addiction Therapeutics - Dormant Products 106
Alcohol Addiction – Product Development Milestones 108
Featured News & Press Releases 108
March 05, 2012: Biotie Announces Presentation Of Positive Phase III Results Of Selincro At 20th European Congress Of Psychiatry 108
December 21, 2011: Lundbeck Submits European March keting Authorization Application For Selincro For Treatment Of Alcohol Dependence 109
June 15, 2011: Biotie Completes Phase III Program With Nalmefene In Alcohol Dependence 110
March 29, 2011: Catalyst Announces Commencement Of CPP-109 Investigator-Sponsored Study In Cocaine And Alcohol Co-Dependent Patients 111
January 03, 2011: Lundbeck Reports Positive Results From First Two Nalmefene Phase III Studies In Alcohol Dependence 112
December 08, 2010: Alkermes Announces Positive Phase II Study Results Of ALKS 33 In Alcohol Dependence 113
July 07, 2009: New Data Published By AEterna Zentaris On Its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports Its Use In Alcohol Addiction 114
December 15, 2008: Lundbeck Initiates Phase III Clinical Trials With Nalmefene As A New Method Of Treatment Of Alcohol Dependence 115
January 02, 2008: Nalmefene United Kingdom And Ireland Rights Acquired By Lundbeck 115
May 26, 2003: Merck KGaA Selects Nippon Shinyaku As Japanese Partner For Alcohol Addiction Treatment 116
Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Contact Us 118
Disclaimer 118

List of Tables

Number of Products Under Development for Alcohol Addiction, H1 2012 12
Products under Development for Alcohol Addiction – Comparative Analysis, H1 2012 13
Number of Products under Development by Firms, H1 2012 15
Number of Products under Investigation by Universities/Institutes, H1 2012 17
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 18
Comparative Analysis by Late Stage Development, H1 2012 19
Comparative Analysis by Mid Clinical Stage Development, H1 2012 20
Comparative Analysis by Early Clinical Stage Development, H1 2012 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 22
Products under Development by Firms, H1 2012 23
Products under Investigation by Universities/Institutes, H1 2012 24
Eli Lilly and Firms, H1 2012 26
Tekmira Pharmaceuticals Corp., H1 2012 27
Alkermes, Inc., H1 2012 28
Mitsubishi Tanabe Pharma Corporation, H1 2012 29
Nippon Shinyaku Co., Ltd., H1 2012 30
Catalyst Pharmaceutical Partners, Inc., H1 2012 31
Biotie Therapies Corp., H1 2012 32
Sihuan Pharmaceutical Holdings Group Ltd., H1 2012 33
Assessment by Monotherapy Products, H1 2012 34
Assessment by Combination Products, H1 2012 35
Assessment by Stage and Route of Administration, H1 2012 37
Assessment by Stage and Molecule Type, H1 2012 39
Alcohol Addiction Therapeutics – Drug Profile Updates 102
Alcohol Addiction Therapeutics – Discontinued Products 105
Alcohol Addiction Therapeutics – Dormant Products 106

List of Figures

Number of Products under Development for Alcohol Addiction, H1 2012 12
Products under Development for Alcohol Addiction – Comparative Analysis, H1 2012 13
Products under Development by Firms, H1 2012 14
Products under Investigation by Universities/Institutes, H1 2012 16
Late Stage Products, H1 2012 19
Mid Clinical Stage Products, H1 2012 20
Early Clinical Stage Products, H1 2012 21
Discovery and Pre-Clinical Stage Products, H1 2012 22
Assessment by Monotherapy Products, H1 2012 34
Assessment by Combination Products, H1 2012 35
Assessment by Route of Administration, H1 2012 36
Assessment by Stage and Route of Administration, H1 2012 37
Assessment by Molecule Type, H1 2012 38
Assessment by Stage and Molecule Type, H1 2012 39